Quantcast
Last updated on April 17, 2014 at 8:56 EDT

Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results – Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack

August 15, 2013

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, August 15, 2013 /PRNewswire/ –

Today, Investors’ Reports announced new research reports highlighting Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI),
Nektar Therapeutics (NASDAQ: NKTR), Sequenom Inc. (NASDAQ: SQNM), and Merrimack
Pharmaceuticals, Inc. (NASDAQ: MACK). Today’s readers may access these reports free of
charge – including full price targets, industry analysis and analyst ratings – via the
links below.

Alnylam Pharmaceuticals, Inc. Research Report

On August 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) reported its consolidated
Q2 2013 financial results with total revenues of $8.7 million, compared to $20.9 million
in Q2 2012. R&D expenses increased by 11.5% YoY to $24.2 million and GAAP net loss for the
quarter totaled $18.2 million, or $0.29 per share, compared to a net loss of $13 million,
or $0.25 per share, in Q2 2012. Michael Mason, Vice President, Finance and Treasurer of
Alnylam said, “Alnylam continues to maintain a solid balance sheet, ending this second
quarter with $380 million in cash. We remain on track to end 2013 with greater than $320
million, which will continue to provide us with a strong balance sheet to execute on our
business plan and advance our RNAi therapeutics through clinical trials and toward the
market.” Alnylam anticipates that its cash, cash equivalents and total marketable
securities balance will be more than $320 million at December 31, 2013. The Full Research
Report on Alnylam Pharmaceuticals, Inc. – including full detailed breakdown, analyst
ratings and price targets – is available to download free of charge at: [

http://www.investorsreports.com/report/2013-08-13/ALNY]

Infinity Pharmaceuticals, Inc. Research Report

On August 8, 2013, Infinity Pharmaceuticals Inc. (Infinity) reported its Q2 2013
financial results with no revenue recorded for the period compared to revenue of $21.9
million in Q2 2012. Infinity informed that Q2 2012 revenue was mainly composed of
reimbursed research and development (R&D) services performed under a previous strategic
alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International
Corporation Limited. Net loss for the quarter totaled $32.6 million or $0.68 per share
against $14.7 million or $0.54 per share in Q2 2012. R&D expenses totaled $26.1 million
compared to $28.5 million in Q2 2012, which decreased primarily due to the discontinuation
of the development of Hedgehog pathway program. For 2013, the Company anticipates net loss
in the range of $135 million to $145 million. The Full Research Report on Infinity
Pharmaceuticals, Inc. – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at: [

http://www.investorsreports.com/report/2013-08-13/INFI]

Nektar Therapeutics Research Report

On August 8, 2013, Nektar Therapeutics (Nektar) reported its Q2 2013 financial results
with revenue of $33.9 million compared to $23.7 million in Q2 2012. Net loss for the
quarter totaled $42.7 million or $0.37 loss per share, compared to $34.3 million or $0.30
loss per share in Q2 2012. R&D expenses totaled $52.2 million compared to $33.2 million in
Q2 2012. According to Nektar, the increase in R&D expenses reflected the costs of
different clinical trials. Howard W. Robin, President and CEO of Nektar said, “I am very
pleased with Nektar’s performance this year. We are on track to report high-level results
from the Phase 2 efficacy study of NKTR-181 in chronic pain patients this summer. Finally,
we recently completed enrollment in our Phase 3 study of NKTR-102 ahead of schedule.” The
Full Research Report on Nektar Therapeutics – including full detailed breakdown, analyst
ratings and price targets – is available to download free of charge at: [

http://www.investorsreports.com/report/2013-08-13/NKTR]

Sequenom Inc. Research Report

On August 1, 2013, Sequenom Inc. (Sequenom) and CombiMatrix Corp. jointly announced
that the Sequenom Center for Molecular Medicine LLC and CombiMatrix have entered into a
collaboration agreement to market chromosomal microarray analysis (CMA) testing services
to widen and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and
their patients. Bill Welch, President and COO of Sequenom, Inc. said, “The MaterniT21 PLUS
test is the premier, noninvasive prenatal test on the market today, and for an important
group of patients a chromosomal microarray test can be a significant adjunct for a
comprehensive prenatal analysis. CombiMatrix specializes in CMA and their technology helps
further expand our product offering in the growing prenatal genetic testing marketplace.”
The Full Research Report on Sequenom Inc. – including full detailed breakdown, analyst
ratings and price targets – is available to download free of charge at: [

http://www.investorsreports.com/report/2013-08-13/SQNM]

Merrimack Pharmaceuticals, Inc. Research Report

On August 8, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) reported its Q2 2013
financial results with collaboration revenues of $18.5 million compared to $12.1 million
in Q2 2012. Net loss for the quarter totaled $30.3 million or $0.31 per share compared to
net loss of $20.1 million or $0.22 per share in Q2 2012. R&D expenses totaled $42.5
million compared to $28.8 million in Q2 2012. Merrimack informed that the increase in R&D
expenses is primarily attributable to ongoing clinical trials. Robert Mulroy, President
and CEO of Merrimack said, “We are pleased with a strong quarter of progress advancing our
pipeline of six novel therapeutic candidates. We remain on track for a robust set of
milestones in the months ahead and we remain focused on our goal of delivering
transformative therapies to patients to dramatically improve cancer outcomes.” The Full
Research Report on Merrimack Pharmaceuticals, Inc. – including full detailed breakdown,
analyst ratings and price targets – is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-13/MACK]

EDITOR NOTES:

        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Equity News Network. An outsourced research
services provider has, through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according to the Procedures
outlined by Equity News Network. Equity News Network is not entitled to veto or interfere
in the application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No liability is
accepted by Equity News Network whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Equity News Network expressly disclaims any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Equity News Network does not
(1) guarantee the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The included
information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors’ Reports


Source: PR Newswire